Syntex Cytovene (ganciclovir)
Executive SummarySyntex Cytovene (ganciclovir): The firm's AIDS-related product was not one of the products covered by the FDA-requested Class II recall of all of Taylor Pharmacal's aseptically processed products manufactured after June 1, 1987 ("The Pink Sheet" Oct. 24, T&F-14). Syntex had a contract with Taylor Pharmacal for the manufacture ganciclovir injection, but the contract was dissolved in July or August of this year, the company said. Currently, Syntex has two contract manufacturers of ganciclovir, Ben Venue Labs and Sterling, for both the liquid and the lyophilized formulations.
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.